Vera’s Strong Trutakna Data Heat Up the IgA Nephropathy Drug Race

Vera Therapeutics reported on Sept. 15, 2026, that Trutakna (atacicept-vymj) met all prespecified endpoints in the final Phase 3 ORIGIN 3 analysis for primary IgA nephropathy (IgAN).

Across two years, annualized eGFR decline was 0.6 mL/min/1.73 m² per year with Trutakna versus 5.6 with placebo—a 5.0-point treatment advantage and broadly consistent with the KDIGO goal of limiting decline to under 1 point annually.

The composite risk of kidney-disease progression fell 76%:
11 events with Trutakna versus 38 with placebo, corresponding to a hazard ratio of 0.24. No Trutakna-treated patient required prolonged dialysis, transplant, or died during the two-year period, compared with eight placebo patients.

The results strengthen Vera’s position after Trutakna received accelerated U.S. approval in July 2026 based on proteinuria reduction, and could support conversion to full approval.

The data intensify competition with Otsuka’s Voyxact. Cross-trial comparisons suggest similar kidney-function preservation, although such comparisons are indirect and should not be treated as head-to-head evidence.

Trutakna also produced statistically significant improvements in proteinuria, galactose-deficient IgA1 and hematuria, with a safety profile described as generally comparable to placebo.